文献速递脑血管病

急性缺血性卒中血管内治疗的经济学评价

Economic Evaluation of Endovascular Treatment for Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2021-10-14

本研究基于MR CLEAN试验及其2年随访数据,从社会视角评估血管内治疗联合常规护理相比单纯常规护理的成本效果。干预组平均每例患者成本为126 494美元,对照组为143 331美元,干预组功能独立比例更高且质量调整生命年更多,血管内治疗在临床有效的同时节约成本。

要点

  • 血管内治疗联合常规护理在急性缺血性卒中患者中具有成本节约优势。
  • 干预组功能独立(mRS 0-2)比例37.2%,对照组23.9%,绝对差异13.3%。
  • 干预组每增加一个良好功能结局患者节约18 233美元。

核心结论

  • 血管内治疗联合常规护理相比单纯常规护理在急性缺血性卒中患者中临床有效且节约成本。

研究设计与样本

  • 基于MR CLEAN试验及其2年随访研究数据,从社会视角开展的经济学评价,时间范围为2年。

主要发现

  • 干预组平均每例患者成本为126 494美元,对照组为143 331美元,平均差异为-16 839美元(95% CI,-38 113至5 456)。
  • 干预组功能独立(mRS 0-2)比例为37.2%,对照组为23.9%,绝对差异为13.3%(95% CI,4.0%-22.0%)。
  • 干预组质量调整生命年为0.99,对照组为0.83,平均差异为0.16(95% CI,0.04-0.29)。
  • 血管内治疗优于标准治疗,每增加一个良好结局患者节约18 233美元,每增加一个质量调整生命年节约105 869美元。

临床怎么用

  • 对于急性缺血性卒中患者,血管内治疗联合常规护理可作为具有成本节约价值的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Endovascular treatment for acute ischemic stroke has been proven clinically effective, but evidence of the cost-effectiveness based on real-world data is scarce. The aim of this study was to assess whether endovascular therapy plus usual care is cost-effective in comparison to usual care alone in acute ischemic stroke patients. METHODS: An economic evaluation was performed from a societal perspective with a 2-year time horizon. Empirical data on health outcomes and the use of resources following endovascular treatment were gathered parallel to the MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) and its 2-year follow-up study. Incremental cost-effectiveness ratios were calculated as the extra costs per additional patient with functional independence (modified Rankin Scale score 0-2) and the extra cost per quality-adjusted life year gained. RESULTS: The mean costs per patient in the intervention group were $126 494 versus $143 331 in the control group (mean difference, -$16 839 [95% CI, -$38 113 to $5456]). Compared with patients in the control group, more patients in the intervention group achieved functional independence, 37.2% versus 23.9% (absolute difference, 13.3% [95% CI, 4.0%-22.0%]) and they generated more quality-adjusted life years, 0.99 versus 0.83 (mean difference of 0.16 [95% CI, 0.04-0.29]). Endovascular treatment dominated standard treatment with $18 233 saved per extra patient with a good outcome and $105 869 saved per additional quality-adjusted life year. CONCLUSIONS: Endovascular treatment added to usual care is clinically effective, and cost saving in comparison to usual care alone in patients with acute ischemic stroke. Registration: URL: https://www.trialregister.nl/trial/695; Unique identifier: NL695. URL: https://www.isrctn.com; Unique identifier: ISRCTN10888758.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. van den Berg LA, Berkhemer OA, Fransen PSS, et al. Economic Evaluation of Endovascular Treatment for Acute Ischemic Stroke. Stroke. 2021. PMID: 34645287. doi:10.1161/STROKEAHA.121.034599

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。